{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:04:41Z","timestamp":1791212681023,"version":"4.1.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.drup.2018.01.004","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T12:45:03Z","timestamp":1519217103000},"page":"17-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"special_numbering":"C","title":["Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018"],"prefix":"10.1016","volume":"37","author":[{"given":"Maria C.","family":"Sorbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velia C.","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Y.M.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo F.","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2018.01.004_bib0005","series-title":"Recommendations for Testing, Managing, and Treating Hepatitis C","author":"AASLD-IDSA","year":"2018"},{"key":"10.1016\/j.drup.2018.01.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"issue":"20","key":"10.1016\/j.drup.2018.01.004_bib0015","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.drup.2018.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/cb400100g","article-title":"Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3\/4A protease inhibitors to drug resistance","volume":"8","author":"Ali","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2018.01.004_bib0030","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","article-title":"In a 5-day monotherapy trial, MK-8408 demonstrated potent antiviral activity and improved resistance profile in HCV patients with genotypes 1, 2, and 3 infections [Abstract THU-222]","author":"Asante-Appiah","year":"2016"},{"key":"10.1016\/j.drup.2018.01.004_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/AAC.00363-17","article-title":"Antiviral activity and resistance analysis of NS3\/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons","volume":"61","author":"Asante-Appiah","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0040","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.virol.2013.05.013","article-title":"Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis","volume":"443","author":"Barnard","year":"2013","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.drup.2018.01.004_bib0050","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"10.1016\/j.drup.2018.01.004_bib0055","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1128\/AAC.02777-13","article-title":"In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus","volume":"58","author":"Bilello","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2018.01.004_bib0060","series-title":"The International Liver Congress\u2122 2015, EASL \u2013 European Association for the Study of the Liver","first-page":"S677","article-title":"Resistance analysis of virologic failures in hepatitis c genotype 1-Infected patients treated with Grazoprevir\u202f+\u202fElbasvir\u202f\u00b1\u202fRibavirin: the C-WORTHY study [Abstract P0891]","author":"Black","year":"2015"},{"issue":"1 Suppl","key":"10.1016\/j.drup.2018.01.004_bib0065","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/civ722","article-title":"Grazoprevir, elbasvir, and ribavirin for chronic hepatitis c virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE","volume":"62","author":"Buti","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.drup.2018.01.004_bib0075","doi-asserted-by":"crossref","first-page":"e39652","DOI":"10.1371\/journal.pone.0039652","article-title":"HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"Cento","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2018.01.004_bib0080","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","article-title":"Resistance analyses for ledipasvir\/sofosbuvir-containing regimens in patients infected with chronic HCV who have advanced liver disease or are post liver transplant (SOLAR-1 and -2 studies)","author":"Charlton","year":"2016"},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0085","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/cmdc.201300343","article-title":"Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity","volume":"8","author":"Coburn","year":"2013","journal-title":"ChemMedChem"},{"issue":"27","key":"10.1016\/j.drup.2018.01.004_bib0090","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2018.01.004_bib0095","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI), 2016","article-title":"Retreatment of HCV\/HIV-Coinfected patients who failed 12 weeks of LDV\/SOF [Poster #573]","author":"Curtis","year":"2016"},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0100","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267: a pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DeGoey","year":"2014","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/liv.13327","article-title":"Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies","volume":"37","author":"Di Maio","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.drup.2018.01.004_bib0110","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","author":"Dietz","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2018.01.004_bib0115","series-title":"The International Liver Congress\u2122 2017, EASL \u2013 European Association for the Study of the Liver","first-page":"S525","article-title":"Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome [Abstract FRI-258]","author":"Dietz","year":"2017"},{"key":"10.1016\/j.drup.2018.01.004_bib0120","series-title":"The Liver Meeting\u00ae2017, AASLD \u2013 American Association for the Study of Liver Diseases","article-title":"HCV resistance-associated substitutions (RASs) in patients with HCV genotype 4 and failure to DAA combination therapies and implications for a retreatment [Abstract]","author":"Dietz","year":"2017"},{"key":"10.1016\/j.drup.2018.01.004_bib0125","series-title":"The Liver Meeting\u00ae2013, AASLD \u2013 American Association for the Study of Liver Diseases","article-title":"Deep sequencing of HCV NS5A from a 3-day study of GS-5816 monotherapy confirms the potency of GS-5816 against pre-existing genotype 1\u20133 NS5A resistance-associated variants","author":"Doehle","year":"2013"},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2014.10.007","article-title":"Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection","volume":"148","author":"Dore","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2018.01.004_bib0140","series-title":"International Workshop on Antiviral Drug Resistance","article-title":"The prevalence of HCV NS5A nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir\/sofosbuvir+ RBV in the phase 3 ION study","author":"Dvory-Sobol","year":"2014"},{"key":"10.1016\/j.drup.2018.01.004_bib0145","series-title":"The Liver Meeting\u00ae2017, AASLD \u2013 American Association for the Study of Liver Diseases","article-title":"Susceptibility to voxilaprevir of NS3 resistance-associated substitutions and clinical isolates from direct-acting antiviral-experienced and \u2013 naive patients [Abstract 1176]","author":"Dvory-Sobol","year":"2017"},{"key":"10.1016\/j.drup.2018.01.004_bib0150","series-title":"Recommendations on Treatment of Hepatitis C 2016, Update of September 2016","author":"EASL","year":"2017"},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0155","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.drup.2018.01.004_bib0160","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.drup.2018.01.004_bib0165","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.drup.2018.01.004_bib0170","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0175","doi-asserted-by":"crossref","first-page":"ofw52","DOI":"10.1093\/ofid\/ofw052","article-title":"Pre-existence and persistence of resistant minority hepatitis C virus variants in genotype 1-infected patients treated with Simeprevir\/Peginterferon\/Ribavirin","volume":"3","author":"Fevery","year":"2016","journal-title":"Open Forum Infect. Dis."},{"issue":"7","key":"10.1016\/j.drup.2018.01.004_bib0180","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0185","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent","volume":"63","author":"Forns","year":"2015","journal-title":"J. Hepatol."},{"issue":"27","key":"10.1016\/j.drup.2018.01.004_bib0190","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2018.01.004_bib0195","series-title":"The Liver Meeting\u00ae2016, AASLD \u2013 American Association for the Study of Liver Diseases","article-title":"Patients with HCV GT 1\/4 infection and compensated cirrhosis, without baseline NS5A RASs, could be treated with SOF\u2009+\u2009NS5A inhibitor for 12 weeks without RBV [Poster 1911]","author":"Fourati","year":"2016"},{"key":"10.1016\/j.drup.2018.01.004_bib0200","article-title":"In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir","author":"Friborg","year":"2014","journal-title":"Infect. Dis. Therapy"},{"issue":"9","key":"10.1016\/j.drup.2018.01.004_bib0205","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"14","key":"10.1016\/j.drup.2018.01.004_bib0210","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","article-title":"Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052","volume":"85","author":"Fridell","year":"2011","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0215","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0220","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2018.01.004_bib0230","series-title":"The Liver Meeting\u00ae2015, AASLD \u2013 American Association for the Study of Liver Diseases","first-page":"322A","article-title":"The emergence of NS5\u2009B resistant associated variant S282T after sofosbuvir based treatment [Abstract]","author":"Gane","year":"2015"},{"key":"10.1016\/j.drup.2018.01.004_bib0235","series-title":"The Liver Meeting\u00ae2015, AASLD \u2013 American Association for the Study of Liver Diseases","article-title":"Resistance analysis of treatment-na\u00efve and DAA-experienced genotype 1 patients with and without cirrhosis who received short-duration treatment with Sofosbuvir\/Velpatasvir\u202f+\u202fGS-9857 [Abstract 713]","author":"Gane","year":"2015"},{"key":"10.1016\/j.drup.2018.01.004_bib0240","article-title":"Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3\/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with HCV genotype 1 or 3 infections","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"issue":"7294","key":"10.1016\/j.drup.2018.01.004_bib0245","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0250","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1021\/ml300017p","article-title":"Discovery of MK-5172: a macrocyclic hepatitis C virus NS3\/4a protease inhibitor","volume":"3","author":"Harper","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.drup.2018.01.004_bib0255","article-title":"Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives","author":"Harrington","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0260","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","article-title":"Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study","volume":"49","author":"Hayashi","year":"2014","journal-title":"J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0265","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00535-015-1120-x","article-title":"Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study","volume":"51","author":"Hayashi","year":"2016","journal-title":"J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0270","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"9986","key":"10.1016\/j.drup.2018.01.004_bib0275","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"Hezode","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2018.01.004_bib0280","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","first-page":"S753","article-title":"C-EDGE IBLD: efficacy and safety of Elbasvir\/Grazoprevir in patients with chronic hepatitis C virus infection and inherited blood disorders [Abstract SAT-128]","author":"Hezode","year":"2016"},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0285","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.28491","article-title":"Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen","volume":"63","author":"Hezode","year":"2016","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0290","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"Howe","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drup.2018.01.004_bib0295","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI), 2016","article-title":"Genotypic and phenotypic characterization of clinical HCV NS5A drug resistance [Abstract 579]","author":"Huang","year":"2016"},{"key":"10.1016\/j.drup.2018.01.004_bib0300","article-title":"Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1","author":"Iio","year":"2016","journal-title":"J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0305","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","article-title":"Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies","volume":"49","author":"Izumi","year":"2014","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.drup.2018.01.004_bib0310","series-title":"JSH Guidelines for the Management of Hepatitis C Virus Infection: a Update for Genotype 1","author":"JSH","year":"2014"},{"key":"10.1016\/j.drup.2018.01.004_bib0315","series-title":"The Liver Meeting\u00ae2015, AASLD \u2013 American Association for the Study of Liver Diseases","article-title":"Prevalence and impact of baseline NS5A resistance associated variants (RAVs) on the efficacy of Elbasvir\/Grazoprevir (EBR\/GZR) against GT1a infection [Abstract LB22]","author":"Jacobson","year":"2015"},{"key":"10.1016\/j.drup.2018.01.004_bib0320","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.01.050","article-title":"Safety and efficacy of Elbasvir\/Grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0325","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1128\/AAC.01953-15","article-title":"Substitutions at NS3 Residue 155: 156, or 168 of Hepatitis C Virus Genotypes 2\u20136 Induce Complex Patterns of Protease Inhibitor Resistance","volume":"59","author":"Jensen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0330","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhep.2015.02.018","article-title":"Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders","volume":"63","author":"Jensen","year":"2015","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0335","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1128\/AAC.01578-13","article-title":"In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir","volume":"57","author":"Jiang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0340","doi-asserted-by":"crossref","first-page":"e0155869","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV] \u2013 a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0345","doi-asserted-by":"crossref","first-page":"418","DOI":"10.7150\/ijms.15519","article-title":"Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan","volume":"13","author":"Kanda","year":"2016","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0350","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0355","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","article-title":"Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir","volume":"58","author":"Karino","year":"2013","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0360","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In vitro activity and resistance profile of dasabuvir: a nonnucleoside hepatitis C virus polymerase inhibitor","volume":"59","author":"Kati","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2018.01.004_bib0365","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2014.04.008","article-title":"Resistance to hepatitis C virus protease inhibitors","volume":"8","author":"Kieffer","year":"2014","journal-title":"Curr. Opin. Virol."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0370","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","article-title":"Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of Elbasvir and Grazoprevir","volume":"152","author":"Komatsu","year":"2017","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.drup.2018.01.004_bib0375","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.drup.2018.01.004_bib0380","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0385","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir: an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0390","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.02606-15","article-title":"Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir-ritonavir and ombitasvir","volume":"60","author":"Krishnan","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2018.01.004_bib0395","series-title":"The International Liver Congress\u2122 2017, EASL \u2013 European Association for the Study of the Liver","first-page":"S500","article-title":"Pooled resistance analysis in HCV genotype 1\u20136-infected patients treated with glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials [Abstract FRI-205]","author":"Krishnan","year":"2017"},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0400","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0405","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","article-title":"Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis","volume":"62","author":"Kumada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2018.01.004_bib0410","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28467","article-title":"Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study","author":"Kwo","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0415","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/AAC.05166-11","article-title":"In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335","volume":"56","author":"Lagace","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0420","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1128\/AAC.00051-16","article-title":"The combination of grazoprevir: a hepatitis C virus (HCV) NS3\/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons","volume":"60","author":"Lahser","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0425","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0430","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0435","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","author":"Lawitz","year":"2013","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0440","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/j.gastro.2015.07.001","article-title":"Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis","volume":"149","author":"Lawitz","year":"2015","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0445","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/jvh.12435","article-title":"A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1\u20134 hepatitis C virus","volume":"22","author":"Lawitz","year":"2015","journal-title":"J. Viral Hepat."},{"issue":"9973","key":"10.1016\/j.drup.2018.01.004_bib0450","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2018.01.004_bib0455","series-title":"The International Liver Congress\u2122 2015, EASL \u2013 European Association for the Study of the Liver","first-page":"S192","article-title":"Retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvi\/sofosbuvir for 24 weeks [Abstract O005]","author":"Lawitz","year":"2015"},{"key":"10.1016\/j.drup.2018.01.004_bib0460","series-title":"The Liver Meeting\u00ae2015, AASLD \u2013 American Association for the Study of Liver Diseases Vol. 62","first-page":"119A","article-title":"Characterization of HCV resistance from a 3-day monotherapy study of GS-9857, a novel pangenotypic NS3\/4A protease inhibitor [Abstract 718]","author":"Lawitz","year":"2015"},{"key":"10.1016\/j.drup.2018.01.004_bib0465","article-title":"Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST -2)","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2018.01.004_bib0470","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0475","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","article-title":"Virologic response and characterisation of HCV genotype 2\u20136 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"Lenz","year":"2013","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0480","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0485","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2018.01.004_bib0490","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2018.01.004_bib0495","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coviro.2014.04.012","article-title":"Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance","volume":"8","author":"Lim","year":"2014","journal-title":"Curr. Opin. Virol."},{"issue":"11","key":"10.1016\/j.drup.2018.01.004_bib0500","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a: 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0505","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1128\/AAC.00677-09","article-title":"MK-7009: a potent and selective inhibitor of hepatitis C virus NS3\/4A protease","volume":"54","author":"Liverton","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0510","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0515","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2018.01.004_bib0520","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.antiviral.2016.03.004","article-title":"HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials","volume":"130","author":"Ludmerer","year":"2016","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0525","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"9954","key":"10.1016\/j.drup.2018.01.004_bib0530","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0535","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0540","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamainternmed.2013.12505","article-title":"The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry","volume":"174","author":"McCombs","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0545","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","author":"McGivern","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2018.01.004_bib0550","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","article-title":"Next-Generation sequencing analysis of NS5A and NS5\u2009B minor resistance-associated variants in patients with HCV genotype 3 infection who failed treatment with daclatasvir plus sofosbuvir. poste#171","author":"McPhee","year":"2016"},{"issue":"7","key":"10.1016\/j.drup.2018.01.004_bib0555","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0560","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"McPhee","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0565","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3851\/IMP2729","article-title":"Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b","volume":"19","author":"McPhee","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.drup.2018.01.004_bib0570","series-title":"The International Liver Congress\u2122 2015, EASL \u2013 European Association for the Study of the Liver","article-title":"Next-generation sequencing analysis of NS5A and NS5A minor resistance-associated variants in patients with HCV genotype 3 infection who failed treatment with daclatasvir plus sofosbuvi [Abstract FRI-171]","author":"McPhee","year":"2015"},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0575","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0580","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2014.12.031","article-title":"Efficacy and safety of simeprevir with PegIFN\/ribavirin in naive or experienced patients infected with chronic HCV genotype 4","volume":"62","author":"Moreno","year":"2015","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0585","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.drup.2018.01.004_bib0590","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1021\/jm501291c","article-title":"Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition","volume":"57","author":"Nettles","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2018.01.004_bib0595","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI), 2014","article-title":"ABT-493, a potent HCV NS3\/4A protease inhibitor with broad genotype coverage [Abstract 636]","author":"Ng","year":"2014"},{"key":"10.1016\/j.drup.2018.01.004_bib0600","series-title":"The Liver Meeting\u00ae2016","article-title":"Analysis of HCV variants in the MAGELLAN-I study (Part 1): ABT-493 and ABT-530 combination therapy of genotype 1-infected patients who had failed prior direct acting antiviral-containing regimens [Poster 849]","author":"Ng","year":"2016"},{"key":"10.1016\/j.drup.2018.01.004_bib0605","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","first-page":"S409","article-title":"Analysis of HCV genotype 2 and 3 variants in patients treated with combination therapy of next generation HCV direct-acting antiviral agents ABT-493 and ABT-530 [Abstract THU-240]","author":"Ng","year":"2016"},{"key":"10.1016\/j.drup.2018.01.004_bib0610","series-title":"The International Liver Congress\u2122 2017, EASL \u2013 European Association for the Study of the Liver","first-page":"S324","article-title":"Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes [Abstract THU-305]","author":"Ng","year":"2017"},{"issue":"8","key":"10.1016\/j.drup.2018.01.004_bib0615","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus","volume":"88","author":"Ogata","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0620","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.drup.2018.01.004_bib0625","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/AAC.01209-12","article-title":"Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir","volume":"56","author":"Pelosi","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2018.01.004_bib0630","series-title":"The International Liver Congress\u2122 2011, EASL \u2013 European Association for the Study of the Liver","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","author":"Pilot-Matias","year":"2011"},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0635","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2018.01.004_bib0640","series-title":"The International Liver Congress\u2122 2017, EASL \u2013 European Association for the Study of the Liver","first-page":"S708","article-title":"Resistance analysis in the MAGELLAN-1 Study (Part 2): Glecaprevir\/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3\/4A protease and\/or NS5A inhibitors [Abstract SAT-204]","author":"Pilot-Matias","year":"2017"},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0645","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCVC","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0650","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.drup.2018.01.004_bib0655","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.drup.2018.01.004_bib0660","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","article-title":"Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection","volume":"313","author":"Poordad","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.drup.2018.01.004_bib0665","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/liv.13067","article-title":"High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir\/ritonavir and ribavirin against hepatitis C virus genotype 3 infection","volume":"36","author":"Poordad","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.drup.2018.01.004_bib0670","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","first-page":"S768","article-title":"High efficacy of ABT-493 and ABT-530 in HCV genotype-1 infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I study [Abstract SAT-157]","author":"Poordad","year":"2016"},{"key":"10.1016\/j.drup.2018.01.004_bib0675","series-title":"The Liver Meeting\u00ae2016, AASLD \u2013 American Association for the Study of Liver Diseases","article-title":"Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir and voxilaprevir for 8 and 12 weeks from phase 2 studies [Poster 846]","author":"Reau","year":"2016"},{"issue":"8","key":"10.1016\/j.drup.2018.01.004_bib0680","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0685","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cgh.2013.09.067","article-title":"Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis","volume":"12","author":"Rodriguez-Torres","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.drup.2018.01.004_bib0690","doi-asserted-by":"crossref","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog."},{"issue":"10003","key":"10.1016\/j.drup.2018.01.004_bib0695","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2018.01.004_bib0700","series-title":"The Liver Meeting\u00ae2014, AASLD \u2013 American Association for the Study of Liver Diseases","first-page":"1128A","article-title":"Baseline and post-baseline resistance analyses of phase 2\/3 studies of Ledipasvir\/Sofosbuvir\u2009\u00b1\u2009RBV [Abstract 1926]","author":"Sarrazin","year":"2014"},{"key":"10.1016\/j.drup.2018.01.004_bib0705","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80\u2009K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2018.01.004_bib0710","series-title":"The International Liver Congress\u2122 2015, EASL \u2013 European Association for the Study of the Liver","first-page":"S620","article-title":"The prevalence and the effect of HCV NS5A resistance-associated variants in patients with compensated cirrhosis treated with Ledipasvir\/Sofosbuvir\u2009\u00b1\u2009RBV [Abstract P0773]","author":"Sarrazin","year":"2015"},{"key":"10.1016\/j.drup.2018.01.004_bib0715","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-Associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2018.01.004_bib0720","series-title":"The International Liver Congress\u2122 2017, EASL \u2013 European Association for the Study of the Liver","first-page":"S299","article-title":"No impact of RASs on the high efficacy of SOF\/VEL\/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis on the POLARIS-1 and POLARIS-4 studies [Abstract THU-248]","author":"Sarrazin","year":"2017"},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0725","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.drup.2018.01.004_bib0730","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1128\/AAC.01229-15","article-title":"Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir\/ritonavir","volume":"59","author":"Schnell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2018.01.004_bib0735","series-title":"The Liver Meeting\u00ae2016, AASLD \u2013 American Association for the Study of Liver Diseases","first-page":"427A","article-title":"Combined resistance, demographic, and phylogenetic analysis of HCV genotype 4-infected patients treated with ombitasvir\/paritaprevir\/r\u2009+\/\u2212 ribavirin in the PEARL-I and AGATE-I studies [Poster 866]","author":"Schnell","year":"2016"},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0740","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.02929-15","article-title":"Hepatitis C Virus Genotype 1\u20136 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle","volume":"60","author":"Serre","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0745","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2018.01.004_bib0750","series-title":"International Committee on Taxonomy of Viruses (ICTV). HCV Classification","author":"Smith","year":"2018"},{"issue":"11","key":"10.1016\/j.drup.2018.01.004_bib0755","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/cb5006118","article-title":"Structural analysis of asunaprevir resistance in HCV NS3\/4A protease","volume":"9","author":"Soumana","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"36","key":"10.1016\/j.drup.2018.01.004_bib0760","doi-asserted-by":"crossref","first-page":"11850","DOI":"10.1021\/jacs.6b06454","article-title":"Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3\/4A protease","volume":"138","author":"Soumana","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"17","key":"10.1016\/j.drup.2018.01.004_bib0765","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1517\/14656566.2014.972364","article-title":"Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C","volume":"15","author":"Stirnimann","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0770","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"Sulkowski","year":"2015","journal-title":"JAMA"},{"issue":"9973","key":"10.1016\/j.drup.2018.01.004_bib0775","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2018.01.004_bib0780","series-title":"Conference on Retroviruses and Opportunistic Infections (CRO), 2016","article-title":"Effect of baseline resistance-Associated variants on SVR with the 3D regimen plus RBV [Abstract 6LB-3113]","author":"Sulkowski","year":"2016"},{"issue":"8","key":"10.1016\/j.drup.2018.01.004_bib0785","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.drup.2018.01.004_bib0790","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/hep.25581","article-title":"Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052","volume":"55","author":"Sun","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2018.01.004_bib0795","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","first-page":"S139","article-title":"European RAVs database: frequency and characteristics of RAVs in treatment-naive and DAA-experienced patients [Abstract PS007]","author":"Susser","year":"2016"},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0800","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0805","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1\u20136 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.drup.2018.01.004_bib0810","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","article-title":"L159F and V321A sofosbuvir-associated hepatitis C virus NS5\u202fB substitutions","volume":"213","author":"Svarovskaia","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drup.2018.01.004_bib0815","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","first-page":"S681","article-title":"Preclinical profile of the pan-genotypic HCV NS3\/4A protease inhibitor GS-9857 [Abstract P0899]","author":"Taylor","year":"2015"},{"issue":"5","key":"10.1016\/j.drup.2018.01.004_bib0820","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5\u202fB polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"21","key":"10.1016\/j.drup.2018.01.004_bib0825","doi-asserted-by":"crossref","first-page":"11124","DOI":"10.1128\/JVI.01217-10","article-title":"Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing","volume":"84","author":"Verbinnen","year":"2010","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0830","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1128\/AAC.01444-15","article-title":"In vitro activity of simeprevir against hepatitis C virus genotype 1 clinical isolates and its correlation with NS3 sequence and site-directed mutants","volume":"59","author":"Verbinnen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.drup.2018.01.004_bib0835","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy","volume":"67","author":"Vicenti","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2018.01.004_bib0840","series-title":"The International Liver Congress\u2122 2015, EASL \u2013 European Association for the Study of the Liver","article-title":"Efficacy of an 8-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, non-cirrhotic HCV genotype 1b infection","author":"Vierling","year":"2015"},{"key":"10.1016\/j.drup.2018.01.004_bib0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2017.03.027","article-title":"Treatment of Hepatitis C virus infection in Italy: a consensus report from an expert pane","author":"Vigano","year":"2017","journal-title":"Dig. Liver Dis."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0850","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.06169-11","article-title":"In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0855","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.01874-12","article-title":"In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.drup.2018.01.004_bib0860","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1\u20136: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.drup.2018.01.004_bib0865","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/civ874","article-title":"Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens","volume":"62","author":"Wilson","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.drup.2018.01.004_bib0870","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2018.01.004_bib0875","series-title":"The International Liver Congress\u2122 2017, EASL \u2013 European Association for the Study of the Liver","first-page":"S303","article-title":"No impact of RASs on the high efficacy of SOF\/VEL\/VOX for 8 weeks in DAA-na\u00efve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies [Abstract THU-257]","author":"Wyles","year":"2017"},{"key":"10.1016\/j.drup.2018.01.004_bib0880","series-title":"International Workshop on Hepatitis C Resistance and New Compounds","article-title":"In vitro selection of resistance to sofosbuvir in GT 2a, 2b, 3a, 4a, 5a and 6a replicons [Abstract O_01B]","author":"Xu","year":"2013"},{"issue":"17","key":"10.1016\/j.drup.2018.01.004_bib0885","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.drup.2018.01.004_bib0890","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drup.2018.01.004_bib0895","series-title":"The Liver Meeting\u00ae2016, AASLD \u2013 American Association for the Study of Liver Diseases","first-page":"59","article-title":"A randomized, controlled, phase 3 trial of sofosbuvir\/velpatasvir\/voxilaprevir or sofosbuvir\/velpatasvir for 12 weeks in direct acting antiviral-experienced patients with genotype 1\u20136 HCV infection: the POLARIS-4 study [Abstract]","author":"Zeuzem","year":"2016"},{"key":"10.1016\/j.drup.2018.01.004_bib0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.drup.2018.01.004_bib0905","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiv379","article-title":"NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection","volume":"213","author":"Zhou","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drup.2018.01.004_bib0910","series-title":"The International Liver Congress\u2122 2016, EASL \u2013 European Association for the Study of the Liver","first-page":"S407","article-title":"High sustained virologic response rates in patients infected with HCV genotype 2 with baseline NS5A polymorphisms treated with daclatasvir-Based regimens [Abstract 234]","author":"Zhou","year":"2016"}],"updated-by":[{"DOI":"10.1016\/j.drup.2018.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000}}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764618300128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764618300128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:54:20Z","timestamp":1761281660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764618300128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":182,"alternative-id":["S1368764618300128"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2018.01.004","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2018.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}